Peanut allergy study

PEANUT ALLERGY STUDY

Registry ID

EUCTR2015-004257-41

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

AIMMUNE THERAPEUTICS

Start date

2016-04-13

Completion date

2018-07-02

Last update

2026-08-16

Conditions

• Peanut Allergy

Summary

The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanutallergic children and adults (ages 4-55 years, inclusive).

Locations

• , , Germany
• , , Sweden
• , , UK
• , , Denmark
• , , Ireland
• , , Netherlands
• , , Spain
• , , Italy

Related clinical trials

• Safety of MOON101 for the Treatment of Peanut Allergy
• Efficacy of Tezepelumab in Peanut Oral Immunotherapy
• UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
• Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
• Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
• Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

View on source registry